{"groups":[{"description":"Participants received bodyweight and body surface area (BSA) stratified dose of midostaurin 30 mg/m\\^2 twice daily (bid) through oral route. The total daily dose in 30 mg/m\\^2 bid cohort was 60 mg/m\\^2.","id":"FG000","title":"Cohort 1: Midostaurin (30 Milligrams/Meters^2)"},{"description":"Participants received bodyweight and BSA stratified dose of midostaurin 60 mg/m\\^2 bid through oral route. The total daily dose in 60 mg/m\\^2 bid cohort was 120 mg/m\\^2.","id":"FG001","title":"Cohort 2: Midostaurin (60 mg/m^2)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}],"type":"Withdrawal by participants"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"11"}],"type":"Disease progression"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"4"}],"type":"New cancer therapy"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"15"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"15"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 22 participants were enrolled in the study.","recruitmentDetails":"The study was conducted at 8 centers in 5 countries."}